SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
36,500
-1,250 (-3.31%)
At close: Aug 21, 2026

SK bioscience Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
659,267651,368267,545369,506456,726929,001
Other Revenue
-0-0---0-
659,267651,368267,545369,506456,726929,001
Revenue Growth
23.25%143.46%-27.59%-19.10%-50.84%-
Cost of Revenue
565,739576,192237,466227,681217,443358,968
Gross Profit
93,52775,17730,079141,824239,283570,033
Selling, General & Admin
130,211110,99387,05660,84161,80146,027
Research & Development
72,83869,86171,35385,74357,96047,250
Amortization of Goodwill & Intangibles
12,88710,8094,2201,938963.13680.01
Other Operating Expenses
1,7301,4111,2741,417664.99388.56
Operating Expenses
224,781198,678168,511153,812124,26995,813
Operating Income
-131,253-123,502-138,431-11,988115,014474,220
Interest Expense
-12,674-9,399-3,685-1,398-2,461-3,427
Interest & Investment Income
17,51115,6746,97813,5554,8541,517
Currency Exchange Gain (Loss)
-8,406-13,0123,13713,32516,506-1,662
Other Non Operating Income (Expenses)
-1,8132,9554,474-18,722-28,620-434.77
EBT Excluding Unusual Items
-136,635-127,284-127,527-5,228105,293470,212
Gain (Loss) on Sale of Investments
4,10310,44424,16213,77736,875892.14
Gain (Loss) on Sale of Assets
31,35430,97914,259-68.06-434.623.62
Asset Writedown
---1.41-1,154--
Pretax Income
-101,178-85,860-89,1077,327141,733471,128
Income Tax Expense
-15,605-29,687-38,990-14,99019,281115,989
Earnings From Continuing Operations
-85,574-56,173-50,11722,318122,452355,139
Minority Interest in Earnings
875-1,251-3,764---
Net Income
-84,699-57,424-53,88122,318122,452355,139
Net Income to Common
-84,699-57,424-53,88122,318122,452355,139
Net Income Growth
----81.77%-65.52%-
Shares Outstanding (Basic)
787877777773
Shares Outstanding (Diluted)
787877777774
Shares Change
0.59%1.51%0.24%-0.01%4.32%-
EPS (Basic)
-1080.31-732.77-697.93290.651596.184844.07
EPS (Diluted)
-1080.54-733.00-698.00290.001590.004810.00
EPS Growth
----81.76%-66.94%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-134,749-80,584-292,433-14,114-197,951493,686
Free Cash Flow Per Share
-1718.70-1028.30-3787.93-183.27-2570.086686.61
Gross Margin
14.19%11.54%11.24%38.38%52.39%61.36%
Operating Margin
-19.91%-18.96%-51.74%-3.24%25.18%51.05%
Profit Margin
-12.85%-8.82%-20.14%6.04%26.81%38.23%
Free Cash Flow Margin
-20.44%-12.37%-109.30%-3.82%-43.34%53.14%
EBITDA
-33,041-32,486-89,20622,777142,250492,995
EBITDA Margin
-5.01%-4.99%-33.34%6.16%31.15%53.07%
D&A For EBITDA
98,21391,01649,22534,76527,23618,775
EBIT
-131,253-123,502-138,431-11,988115,014474,220
EBIT Margin
-19.91%-18.96%-51.74%-3.24%25.18%51.05%
Effective Tax Rate
----13.60%24.62%
Advertising Expenses
-3,4322,2961,8491,1901,909